China approves 16 locally-made COVID-19 vaccines for clinical trials
The Hindu
China has approved clinical trials for 16 indigenous COVID-19 vaccines, of which six are in the third stage, according to a state-run media report.
The latest vaccines for clinical trials are based on recombinant protein, adenovirus vector, nucleic acid and attenuated influenza-viruses technologies, state-run Xinhua news agency reported on Saturday, citing data from the National Medical Products Administration.
More Related News